339 related articles for article (PubMed ID: 37209211)
1. Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics.
Ding H; Kiguchi N; Dobbins M; Romero-Sandoval EA; Kishioka S; Ko MC
Drugs; 2023 Jun; 83(9):771-793. PubMed ID: 37209211
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic potentials of safe opioid analgesics targeting nociceptin/orphanin FQ peptide receptor].
Kiguchi N; Kishioka S; Ko MC
Nihon Yakurigaku Zasshi; 2021; 156(3):139-144. PubMed ID: 33952840
[TBL] [Abstract][Full Text] [Related]
3. Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics.
Kiguchi N; Ding H; Kishioka S; Ko MC
Curr Top Med Chem; 2020; 20(31):2878-2888. PubMed ID: 32384033
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.
Lin AP; Ko MC
ACS Chem Neurosci; 2013 Feb; 4(2):214-24. PubMed ID: 23421672
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse.
Kiguchi N; Ding H; Ko MC
J Neurosci Res; 2022 Jan; 100(1):191-202. PubMed ID: 32255240
[TBL] [Abstract][Full Text] [Related]
6. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.
Ding H; Czoty PW; Kiguchi N; Cami-Kobeci G; Sukhtankar DD; Nader MA; Husbands SM; Ko MC
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):E5511-8. PubMed ID: 27573832
[TBL] [Abstract][Full Text] [Related]
7. Central N/OFQ-NOP Receptor System in Pain Modulation.
Kiguchi N; Ding H; Ko MC
Adv Pharmacol; 2016; 75():217-43. PubMed ID: 26920014
[TBL] [Abstract][Full Text] [Related]
8. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
9. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
10. Attenuated G protein signaling and minimal receptor phosphorylation as a biochemical signature of low side-effect opioid analgesics.
Dasgupta P; Mann A; Polgar WE; Reinscheid RK; Zaveri NT; Schulz S
Sci Rep; 2022 May; 12(1):7154. PubMed ID: 35504962
[TBL] [Abstract][Full Text] [Related]
11. BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates.
Kiguchi N; Ding H; Cami-Kobeci G; Sukhtankar DD; Czoty PW; DeLoid HB; Hsu FC; Toll L; Husbands SM; Ko MC
Br J Anaesth; 2019 Jun; 122(6):e146-e156. PubMed ID: 30916003
[TBL] [Abstract][Full Text] [Related]
12. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
[TBL] [Abstract][Full Text] [Related]
13. Effects of NOP-Related Ligands in Nonhuman Primates.
Kiguchi N; Ko MC
Handb Exp Pharmacol; 2019; 254():323-343. PubMed ID: 30879202
[TBL] [Abstract][Full Text] [Related]
14. Nociceptin/orphanin FQ receptor and pain: Feasibility of the fourth opioid family member.
Di Cesare Mannelli L; Micheli L; Ghelardini C
Eur J Pharmacol; 2015 Nov; 766():151-4. PubMed ID: 26277324
[TBL] [Abstract][Full Text] [Related]
15. Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.
Cremeans CM; Gruley E; Kyle DJ; Ko MC
J Pharmacol Exp Ther; 2012 Oct; 343(1):72-81. PubMed ID: 22743574
[TBL] [Abstract][Full Text] [Related]
16. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
[TBL] [Abstract][Full Text] [Related]
17. Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.
Schröder W; Lambert DG; Ko MC; Koch T
Br J Pharmacol; 2014 Aug; 171(16):3777-800. PubMed ID: 24762001
[TBL] [Abstract][Full Text] [Related]
18. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
Tzschentke TM; Rutten K
Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomic study of the role of the nociceptin/orphanin FQ receptor and opioid receptors in diabetic hyperalgesia.
Rutten K; Tzschentke TM; Koch T; Schiene K; Christoph T
Eur J Pharmacol; 2014 Oct; 741():264-71. PubMed ID: 25169429
[TBL] [Abstract][Full Text] [Related]
20. Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.
Ko MC; Woods JH; Fantegrossi WE; Galuska CM; Wichmann J; Prinssen EP
Neuropsychopharmacology; 2009 Aug; 34(9):2088-96. PubMed ID: 19279568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
